These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 38202616)

  • 1. Optimized DOX Drug Deliveries via Chitosan-Mediated Nanoparticles and Stimuli Responses in Cancer Chemotherapy: A Review.
    Imran H; Tang Y; Wang S; Yan X; Liu C; Guo L; Wang E; Xu C
    Molecules; 2023 Dec; 29(1):. PubMed ID: 38202616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery.
    Lee JY; Termsarasab U; Lee MY; Kim DH; Lee SY; Kim JS; Cho HJ; Kim DD
    Acta Biomater; 2017 Jul; 57():262-273. PubMed ID: 28483700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of collagen peptide functionalized chitosan nanoparticles by ionic gelation method: An effective carrier system for encapsulation and release of doxorubicin for cancer drug delivery.
    Anandhakumar S; Krishnamoorthy G; Ramkumar KM; Raichur AM
    Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):378-385. PubMed ID: 27770906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: stimuli-responsive carriers, co-delivery and suppressing resistance.
    Ashrafizadeh M; Saebfar H; Gholami MH; Hushmandi K; Zabolian A; Bikarannejad P; Hashemi M; Daneshi S; Mirzaei S; Sharifi E; Kumar AP; Khan H; Heydari Sheikh Hossein H; Vosough M; Rabiee N; Kumar Thakur V; Makvandi P; Mishra YK; Tay FR; Wang Y; Zarrabi A; Orive G; Mostafavi E
    Expert Opin Drug Deliv; 2022 Apr; 19(4):355-382. PubMed ID: 35152815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chitosan functionalized doxorubicin loaded poly(methacrylamide) based copolymeric nanoparticles for enhanced cellular internalization and in vitro anticancer evaluation.
    Manhas P; Cokca C; Sharma R; Peneva K; Wangoo N; Sharma D; Sharma RK
    Int J Biol Macromol; 2024 Feb; 259(Pt 2):129242. PubMed ID: 38199540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catechol-modified chitosan/hyaluronic acid nanoparticles as a new avenue for local delivery of doxorubicin to oral cancer cells.
    Pornpitchanarong C; Rojanarata T; Opanasopit P; Ngawhirunpat T; Patrojanasophon P
    Colloids Surf B Biointerfaces; 2020 Dec; 196():111279. PubMed ID: 32750605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chitosan-tripolyphosphate nanoparticles functionalized with a pH-responsive amphiphile improved the in vitro antineoplastic effects of doxorubicin.
    Nogueira-Librelotto DR; Scheeren LE; Vinardell MP; Mitjans M; Rolim CMB
    Colloids Surf B Biointerfaces; 2016 Nov; 147():326-335. PubMed ID: 27543694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified methods of nanoparticles synthesis in pH-sensitive nano-carriers production for doxorubicin delivery on MCF-7 breast cancer cell line.
    Hamidu A; Mokrish A; Mansor R; Razak ISA; Danmaigoro A; Jaji AZ; Bakar ZA
    Int J Nanomedicine; 2019; 14():3615-3627. PubMed ID: 31190815
    [No Abstract]   [Full Text] [Related]  

  • 10. PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release.
    Scheeren LE; Nogueira DR; Macedo LB; Vinardell MP; Mitjans M; Infante MR; Rolim CM
    Colloids Surf B Biointerfaces; 2016 Feb; 138():117-27. PubMed ID: 26674840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and evaluation of a novel potential carrier for a hydrophilic antitumor drug: Auricularia auricular polysaccharide-chitosan nanoparticles as a delivery system for doxorubicin hydrochloride.
    Xiong W; Li L; Wang Y; Yu Y; Wang S; Gao Y; Liang Y; Zhang G; Pan W; Yang X
    Int J Pharm; 2016 Sep; 511(1):267-275. PubMed ID: 27424168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan-based DDSs for pH/hypoxia dual-triggered DOX delivery: Facile morphology modulation for higher in vitro cytotoxicity.
    Xie P; Liu P
    Carbohydr Polym; 2022 Jan; 275():118760. PubMed ID: 34742449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
    Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
    Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzylguanidine and Galactose Double-Conjugated Chitosan Nanoparticles with Reduction Responsiveness for Targeted Delivery of Doxorubicin to CXCR 4 Positive Tumors.
    Kong F; Tang C; Yin C
    Bioconjug Chem; 2020 Oct; 31(10):2446-2455. PubMed ID: 32991164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diselenide-crosslinked carboxymethyl chitosan nanoparticles for doxorubicin delivery: Preparation and in vivo evaluation.
    Wang J; Liu J; Lu DQ; Chen L; Yang R; Liu D; Zhang B
    Carbohydr Polym; 2022 Sep; 292():119699. PubMed ID: 35725216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biocompatibility studies of intravenously administered ionic-crosslinked chitosan-BSA nanoparticles as vehicles for antitumour drugs.
    Montero N; Pérez E; Benito M; Teijón C; Teijón JM; Olmo R; Blanco MD
    Int J Pharm; 2019 Jan; 554():337-351. PubMed ID: 30439492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitosan-based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy.
    Ashrafizadeh M; Hushmandi K; Mirzaei S; Bokaie S; Bigham A; Makvandi P; Rabiee N; Thakur VK; Kumar AP; Sharifi E; Varma RS; Aref AR; Wojnilowicz M; Zarrabi A; Karimi-Maleh H; Voelcker NH; Mostafavi E; Orive G
    Bioeng Transl Med; 2023 Jan; 8(1):e10325. PubMed ID: 36684100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.
    Kucuksayan E; Bozkurt F; Yilmaz MT; Sircan-Kucuksayan A; Hanikoglu A; Ozben T
    Sci Rep; 2021 Jun; 11(1):13027. PubMed ID: 34158544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-Modified Erythrocyte Membrane-Cloaked Metal-Organic Framework Nanoparticles for Targeted Antitumor Therapy.
    Lin Y; Zhong Y; Chen Y; Li L; Chen G; Zhang J; Li P; Zhou C; Sun Y; Ma Y; Xie Z; Liao Q
    Mol Pharm; 2020 Sep; 17(9):3328-3341. PubMed ID: 32804508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-delivery of doxorubicin and CRISPR/Cas9 or RNAi-expressing plasmid by chitosan-based nanoparticle for cancer therapy.
    Li Q; Lv X; Tang C; Yin C
    Carbohydr Polym; 2022 Jul; 287():119315. PubMed ID: 35422284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.